title: The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma.
abstract: Multiple regions on the chromosome arm 3p are frequently affected by loss of heterozygosity in human cancers. A candidate tumor suppressor gene is TMEM7, at 3p21.3, which encodes a transmembrane protein. TMEM7 is expressed specifically in the liver, and the encoded protein shares substantial sequence homology with human and mouse 28-kDa interferon-alpha (IFN-alpha) responsive protein. In investigation of the possible role of TMEM7 in development of hepatocellular carcinoma (HCC), we examined TMEM7 expression in 20 primary HCC and 18 HCC cell lines and found recurrent functional alterations. Although TMEM7 mRNA was expressed in normal hepatic cells, downregulation or inactivation of the gene was detected in 85% of primary HCC and 33% of HCC cell lines. To identify the mechanisms responsible, we examined genomic deletion and mutation, and also the effect of inhibitors of DNA methyltransferase and histone deacetylase on cells with low or no endogenous TMEM7 expression. Homozygous deletion of TMEM7 was not detected in 17 pairs of human HCC and corresponding noncancerous liver tissues, nor in any of the 18 HCC cell lines. TMEM7 mutation was not detected in the 18 HCC cell lines (low or normal TMEM7 expression). Treatment of two of six cell lines exhibiting downregulation or loss of TMEM7 with 5-aza-2'-deoxycytidine and trichostatin A yielded additive increase in TMEM7 expression, implicating aberrant DNA methylation and histone deacetylation in transcriptional silencing of this gene. Ectopic expression of TMEM7 in two TMEM7-deficient HCC lines suppressed cell proliferation, colony formation, and cell migration in vitro and reduced tumor formation in nude mice. Treatment of two highly invasive HCC cell lines with IFN-alpha for 7 days significantly increased TMEM7 expression and inhibited cell migration. These findings implicate loss of TMEM7 expression in hepatocarcinogenesis and suggest that modification of TMEM7 expression by IFN-alpha may have therapeutic relevance in a subset of HCC.
authors: Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, Building 37, Room 4128, 37 Convent Drive, MSC 4264, Bethesda, MD 20892-4255, USA.
authors: Xiaoling
authors: X
authors: Zhou
authors: Nicholas C
authors: NC
authors: Popescu
authors: George
authors: G
authors: Klein
authors: Stephan
authors: S
authors: Imreh
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000235:genetics*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019175:DNA Methylation; D000077209:Decitabine; D044127:Epigenesis, Genetic; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D007150:Immunohistochemistry; D016898:Interferon-alpha / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000235:genetics*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D011401:Promoter Regions, Genetic; D017386:Sequence Homology, Amino Acid
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D016898:Interferon-alpha; C012589:trichostatin A; D000077209:Decitabine; D001374:Azacitidine
references: Cancer Lett. 2003 Mar 10;191(2):155-64
references: 12618328
references: BMC Cancer. 2002 Nov 15;2:29
references: 12433278
references: Hepatology. 2003 Apr;37(4):739-41
references: 12668963
references: Hepatology. 2003 Apr;37(4):852-61
references: 12668978
references: Am J Pathol. 2003 Sep;163(3):1101-7
references: 12937151
references: Genes Chromosomes Cancer. 2003 Dec;38(4):307-21
references: 14566849
references: N Engl J Med. 2003 Nov 20;349(21):2042-54
references: 14627790
references: J Interferon Cytokine Res. 2003 Dec;23(12):745-56
references: 14769151
references: Oncogene. 2004 Feb 12;23(6):1308-13
references: 14647417
references: Cancer Res. 2000 Feb 15;60(4):1049-53
references: 10706123
references: Curr Opin Immunol. 2000 Aug;12(4):419-24
references: 10899033
references: Lab Invest. 2001 Apr;81(4):613-27
references: 11304581
references: Cancer Res. 2001 Nov 15;61(22):8094-9
references: 11719434
references: Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14763-5
references: 11752421
references: Nat Rev Cancer. 2001 Dec;1(3):194-202
references: 11902574
references: Eur J Hum Genet. 2002 Jan;10(1):52-61
references: 11896456
references: Nat Rev Genet. 2002 Jun;3(6):415-28
references: 12042769
references: Nat Genet. 2002 Aug;31(4):339-46
references: 12149612
references: Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15584-9
references: 12438687
references: Nature. 2002 Dec 5;420(6915):563-73
references: 12466851
references: Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903
references: 12477932
references: Oncogene. 2003 Jan 23;22(3):445-50
references: 12545165
references: Oncogene. 2004 Feb 19;23(7):1405-11
references: 14661059
references: Int J Oncol. 2004 Apr;24(4):837-45
references: 15010820
references: N Engl J Med. 1999 Mar 11;340(10):745-50
references: 10072408
references: Hepatology. 1999 Apr;29(4):1208-14
references: 10094966
references: Biofactors. 2004;21(1-4):69-72
references: 15630172
references: Int J Cancer. 2005 Jul 10;115(5):684-9
references: 15704097
references: Clin Cancer Res. 2006 Mar 1;12(5):1412-9
references: 16533763
references: Am J Pathol. 2006 Apr;168(4):1375-84
references: 16565510
references: Cancer Res. 2006 Jun 15;66(12):6361-9
references: 16778214
references: Oncogene. 2003 Mar 27;22(12):1866-71
references: 12660822